araag2/HINT huggingface dataset:
Clinical trial NCT00489710 (phase 2, status: withdrawn)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: talabostat mesylate
SMILES: CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O
Reason stopped: 
    terminated for safety reasons
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Pathologic diagnosis of renal cell carcinoma

               -  Clinical confirmation of metastatic disease required

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques or ≥ 10 mm by spiral CT scan

               -  The following are considered nonmeasurable disease:

                    -  Small lesions (longest diameter < 20 mm by conventional techniques or < 10
                       mm by spiral CT scan)

                    -  Bone lesions

                    -  Leptomeningeal disease

                    -  Ascites

                    -  Pleural or pericardial effusion

                    -  Lymphangitis cutis or pulmonis

                    -  Abdominal masses that are not confirmed and followed by imaging techniques

                    -  Cystic lesions

          -  Progressed after ≥ 1 multikinase inhibitor regimen (i.e., sorafenib tosylate or
             sunitinib malate)

          -  No history of CNS or brain metastasis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8.5 g/dL (no packed red blood cell transfusions within the past 4 weeks)
             (epoetin alfa support allowed)

          -  Bilirubin ≤ 1.5 times the upper limit of normal (ULN) (unless due to Gilbert's
             syndrome)

          -  AST and ALT ≤ 3 times ULN

          -  Creatinine < 2.0 mg/dL

          -  No active serious infections

          -  No other malignancy within the past 5 years except basal cell or nonmetastatic
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  No comorbidity or concurrent condition that would interfere with protocol assessments
             or procedures

          -  No ongoing coagulopathy

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 4 weeks since prior systemic therapy and recovered

          -  Prior radiotherapy allowed as long as the lesion treated is not used to assess
             response

          -  No prior radiotherapy to > 50% of the bone marrow

          -  No prior radiotherapy to index lesions unless there is clearly progressive disease
             within the irradiated area OR measurable disease outside the irradiated area
Clinical trial NCT01640847 (phase 2, status: withdrawn)
Conditions: painful bone metastases, breast carcinoma, non-small cell lung cancer, small cell lung cancer, adenocarcinoma
ICD codes: C4A.52, C44.511, C44.521, D05.00, D05.01, D05.02, D05.10, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: high intensity focused ultrasound (hifu) in combination with thermodox
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological confirmation of breast carcinoma, non-small cell lung cancer, small cell
             lung cancer, or adenocarcinoma of the prostate

          -  Bone metastases index lesion in the ribs, clavicle, scapula, upper extremities,
             pelvis, or posterior aspects of the lumbar vertebra L3-L5 or sacral S1-S5.

          -  Patients will have failed at least one prior attempt or will not be eligible for
             external beam radiation therapy (EBRT)

        Exclusion Criteria:

          -  Greater than 450 mg/m2 of prior free doxorubicin and/or non-heat activated liposomal
             doxorubicin

          -  LVEF < 50%

          -  Significant Cardiac History

          -  Brain Metastases

          -  Contraindication for MR imaging (as incompatible implanted metallic device, weight
             >250 lbs etc) or known intolerance or allergy to MRI contrast agents.
Clinical trial NCT00089102 (phase 2, status: terminated)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: gemcitabine hydrochloride, irinotecan hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed renal cell carcinoma

               -  Locally advanced unresectable or metastatic disease

          -  Unidimensionally measurable disease by physical exam or imaging study

               -  The following are not considered measurable disease:

                    -  Bone only disease

                    -  Pleural or peritoneal effusions

                    -  CNS lesions

                    -  Irradiated lesions unless disease progression was documented after
                       radiotherapy

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  ALT and AST < 3 times upper limit of normal

          -  Bilirubin ≤ 2.0 mg/dL

        Renal

          -  Creatinine ≤ 2.0 mg/dL

        Gastrointestinal

          -  No active inflammatory bowel disease

          -  No significant bowel obstruction

          -  No chronic diarrhea

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study
             participation

          -  No mental incapacitation or psychiatric illness that would preclude giving informed
             consent

          -  No other active malignancy except nonmelanoma skin cancer

          -  No other severe disease that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  At least 4 weeks since prior immunotherapy

          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)

        Chemotherapy

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No concurrent hormones except steroids for adrenal failure, hormones for
             non-disease-related conditions (e.g., insulin for diabetes), or intermittent
             dexamethasone as an antiemetic

        Radiotherapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent palliative radiotherapy

        Surgery

          -  Not specified

        Other

          -  No concurrent participation in another clinical trial
Clinical trial NCT00703365 (phase 2, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib and gemcitabine
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  patient at least 18 years of age with written informed consent prior to enrollment
             into the study.

          -  histologically or cytologically confirmed advanced unresectable and/or metastasis) HCC

          -  Child-Pugh class A or B

          -  Have measurable disease according to RECIST criteria

          -  life expectancy of at least 12 weeks, ECOG 0-2

          -  Have adequate bone marrow reserve and liver and renal function at screening

          -  Practice adequate contraception during study participation

        Exclusion Criteria:

          -  Exclude medical conditions including history of cardiac disease, HIV infection,active
             infection,brain metastastasis or intracranial metastasis,seizure disorder requiring
             medication, history of organ allograft,evidence of or history of bleeding
             diathesis,previous or concurrent cancer with distinct in primary site or histology
             (with exception of cervical carcinoma in situ and treated basal cell carcinoma

          -  Excluded therapies and medications, previous and concomitant : prior systemic
             anticancer chemotherapy or immunotherapy or targeted therapy,hormonal therapy within 2
             weeks,local treatment modality within 4 weeks,radiotherapy within 3 weeks,major
             surgery and unhealed wound within 4 weeks,autologous bone marrow transplant or stem
             cell rescue within 4 months

          -  other condition that may interfere with the patient's participation in the study or
             evaluation of the results
Clinical trial NCT00238615 (phase 2, status: terminated)
Conditions: lung cancer, carcinoma, non-small-cell lung
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, D02.20, D02.21, D02.22
Drugs: docetaxel, carboplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

        Histologically confirmed stage IIIA or IIIB NSCLC

          -  Patients must have measurable disease

          -  No previous chemotherapy, radiation therapy or other systemic therapy for their NSCLC.

          -  Age>18 years

          -  Life expectancy >12 months

          -  ECOG performance status 0-1

          -  Normal organ and marrow function

          -  Medically fit for surgery at time of enrollment.

          -  Women of childbearing potential and men must agree to use adequate contraception prior
             to study entry and for the duration of the study. Women must have a negative pregnancy
             test prior to enrollment.

          -  Ability to understand and willingness to sign the consent form.

        Exclusion Criteria:

          -  Previous chemotherapy, radiation therapy or any other systemic treatment for their
             NSCLC.

          -  Patients receiving any other investigational agents.

          -  Known metastatic disease (brain or any other site)

          -  History of severe hypersensitivity reaction to docetaxel or other drugs formulated
             with polysorbate 80 or with allergic reactions to compounds of similar chemical
             composition to carboplatin or other agents used in the study.

          -  Peripheral neuropathy >grade 1

          -  Uncontrolled concurrent illness

          -  Pregnant women

          -  Weight loss>10% in the past 3 months before diagnosis.

          -  Hyperglycemia - exclusion from PET analysis

          -  HIV positive patients receiving combination anti-retroviral therapy because of
             possible pharmacokinetic interactions with docetaxel and carboplatin or other agents
             administered during the study.
Clinical trial NCT01119105 (phase 2, status: completed)
Conditions: bacterial infections, infection
ICD codes: A49.9, A04.9, A04.8, A49.8, K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: bc-3781, bc-3781, vancomycin
SMILES: C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O, C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients > 18

          -  Documented acute bacterial skin and skin structure infection

        Exclusion Criteria:

          -  Uncomplicated skin and skin structure infection
Clinical trial NCT00353522 (phase 2, status: completed)
Conditions: coronary heart disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: placebo, dalcetrapib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)CC1(CCCCC1)C(=O)NC1=CC=CC=C1SC(=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  CHD or CHD risk equivalent;

          -  body weight <125kg at visit 1.

        Exclusion Criteria:

          -  recent (within 3 weeks of screening) clinically significant coronary events;

          -  history of statin-associated myopathy, or intolerance to statin;

          -  history of malignancy (except for curatively treated basal cell or squamous cell
             cancer of the skin) during the 3 years prior to screening;

          -  exposure to RO4607381 in past 12 months.
Clinical trial NCT00318175 (phase 2, status: completed)
Conditions: systemic scleroderma, skin fibrosis, hand functionality
ICD codes: L94.1, L94.0
Drugs: bosentan (tracleer)
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with systemic sclerosis (diffuse SSc, limited SSc)

          -  ACR criteria fulfilled

          -  Current areas of skin fibrosis due to SSc

          -  Women postmenopausal or negative pre-treatment pregnancy test as well as a reliable
             method of contraception during study treatment and for at least 3 months after study
             treatment termination

          -  Signed informed consent

        Exclusion Criteria:

          -  Severe PAH or interstitial lung disease (WHO class III and IV)

          -  Skin fibrosis and digital ulcers (DUs) due to conditions other than SSc

          -  Systolic BP < 85 mmHg

          -  Hemoglobin concentration < 75% of the lower limit of the normal range

          -  AST and/or ALT values greater than 3 times the upper limit of normal

          -  Moderate to severe hepatic impairment

          -  Severe malabsorption, severe organ failure or any life threatening condition

          -  Breast feeding

          -  Treatment with any of the following drugs: glibenclamide (glyburide), cyclosporine A,
             and tacrolimus 1 week prior to study participation

          -  Treatment with parenteral prostanoids 3 months prior to study participation

          -  Treatment with inhaled, subcutaneous or oral prostanoids 1 month prior to registration

          -  Systemic antibiotics to treat infection of DUs 2 weeks prior to study participation

          -  Current treatment with phosphodiesterase inhibitors such as sildenafil, except for
             intermittent treatment of male erectile dysfunction

          -  Patient with conditions that prevent compliance with the protocol or adhering to
             therapy

          -  Patient who received an investigational product within 1 month preceding screening

          -  Known hypersensitivity to bosentan or any of the excipients
Clinical trial NCT00529503 (phase 2, status: terminated)
Conditions: lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: sgn-40, placebo, rituximab, etoposide, carboplatin, ifosfamide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of de novo or transformed DLBCL, or follicular grade 3b lymphoma.

          -  Received at least four cycles of first-line therapy with R-CHOP, or equivalent.

          -  Best clinical response to first-line therapy of stable disease, partial response, or
             complete response.

          -  At least one measureable lesion that is both greater than or equal to 1.5cm by
             radiographic imaging and by positive FDG-PET scan.

        Exclusion Criteria:

          -  Leptomeningeal or central nervous system lymphoma.

          -  Received any therapy for relapsed or progressive disease except for local radiation,
             steroids, or rituximab.

          -  Received a hematopoietic stem cell transplant.
Clinical trial NCT00655135 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: ldp-02, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 to 80, nonhospitalized, male or nonpregnant, nonlactating females voluntarily
             able to give informed consent.

          -  Crohn's disease of at least 6 months' duration.

          -  Endoscopic and/or histopathological and/or radiological documentation consistent with
             Crohn's disease obtained preferably within 24 months of screening.

          -  Crohn's disease involving the colon and/or the ileum.

          -  CDAI score from 220 to 400 (inclusive) at the time of the Screening visit. The CDAI
             must have remained between 220 and 400 after the 1-week Screening period for the
             patient to be eligible.

          -  Patients may have been receiving oral or topical 5-ASA compounds provided the dosage
             had been stable for at least the 14-day period before the Screening visit. Patients
             were to be maintained on the 5-ASA compound at a constant dose at least through Day
             57.

        Exclusion Criteria:

          -  Patients with evidence of current GI infection (bacterial or parasitic) or significant
             infection within 45 days of the screening visit.

          -  Patients with a serious underlying disease other than Crohn's disease including
             presence or history of malignancy (except basal cell carcinoma) and histological
             evidence of dysplasia.

          -  Patients with significantly impaired liver or renal function. This includes those with
             established chronic liver disease including hepatitis B or C.

          -  Patients with the laboratory abnormalities

          -  Patients using ethanol or consuming illicit drugs which, in the investigator's
             opinion, may interfere with compliance with the study procedures.

          -  Patients with active psychiatric problems which, in the investigator's opinion, may
             interfere with compliance with the study procedures.

          -  Patients who have previously received or who are currently receiving treatment with a
             monoclonal antibody.

          -  Patients receiving any investigational therapy, excluded medications as defined in
             protocol, or any approved therapy in an investigational protocol within 30 days prior
             to screening.

          -  Patients unable to attend all the study visits or comply with study procedures.
Clinical trial NCT00410163 (phase 2, status: completed)
Conditions: leukaemia, lymphocytic, chronic
ICD codes: A87.2, K52.832, D72.111, C91.11, C91.12, C91.10
Drugs: ofatumumab 500mg, ofatumumab 1000mg, fludarabine, cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with active B-CLL and with an indication for treatment

          2. Age ≥ 18 years

          3. Following receipt of verbal and written information about the study, the patient must
             provide signed informed consent before any study related activity is carried out

        Exclusion Criteria:

          1. Any previous treatment for B-CLL or any other treatments that can be considered active
             against B-CLL

          2. Glucocorticoid unless given in doses ≤ 10 mg /day for other indications than B-CLL
             (e.g. asthma)

          3. Known transformation of B-CLL

          4. Known CNS involvement of B-CLL

          5. Past or current malignancy, except for:

               1. Cervical carcinoma Stage 1B or less

               2. Non-invasive basal cell and squamous cell skin carcinoma

               3. Malignant melanoma with a complete response of a duration of > 10 years

               4. Other cancer diagnoses with a complete response of a duration of > 5 years

          6. Chronic or current infectious disease requiring systemic treatment

          7. Clinically significant cardiac disease

          8. Significant concurrent, uncontrolled medical condition

          9. History of significant cerebrovascular disease

         10. Known HIV positive

         11. Positive serology for hepatitis B, unless due to vaccination

         12. Leukapheresis, except as a safety measure before chemotherapy

         13. ECOG Performance Status of 3 or 4

         14. Patients who at the time of inclusion are not expected to be able to complete the
             ofatumumab-FC regimen

         15. Patients who have received treatment with any non-marketed drug substance or
             experimental therapy within 4 weeks prior to Visit 1

         16. Current participation in any other interventional clinical study

         17. Patients known or suspected of not being able to comply with a study protocol (e.g.
             due to alcoholism, drug dependency or psychological disorder)

         18. Breast feeding women or women with a positive pregnancy test at Visit 1

         19. Women of childbearing potential not willing to use adequate contraception for up to
             one year after last dose of ofatumumab. Adequate contraception is defined as hormonal
             birth control or intrauterine device. For patients in the USA the use of a double
             barrier method is also considered adequate.